ADVERTISEMENT

ICICI Direct: Suven Pharma Posts Subdued Q2 Performance Amid High Base 

ICICI Direct: Suven Pharma Posts Subdued Q2 Performance Amid High Base

Hands wearing blue surgical gloves hold brightly coloured pharmaceutical medication,  in this arranged photograph in London, U.K. (Photographer: Chris Ratcliffe/Bloomberg)
Hands wearing blue surgical gloves hold brightly coloured pharmaceutical medication, in this arranged photograph in London, U.K. (Photographer: Chris Ratcliffe/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Suven Pharmaceuticals Ltd.’s Q2 revenues declined 13% YoY to Rs 237.4 crore mainly due to higher base of one-time pharma contract in Q2 FY20.

Pharma segment de-grew 30.3% YoY to Rs 144 crore. Specialty chemicals grew 25.6% YoY to Rs 68 crore.

Ebitda margins contracted 446 basis points to 41.5% amid higher employee cost and other expenditure.

Ebitda declined 21.5% to Rs 98.5 crore. Profit after tax declined 20.4% YoY to Rs 74.1 crore.

Click on the attachment to read the full report:

ICICI Direct Suven Pharma Company Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.